| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AO2: GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE MEASUREMENTS IN 127 RHEUMATOID ARTHRITIS AND 167 OSTEOARTHRITIS PATIENTS IN HUNGARY
|
Szende, A
|
|
2000
|
3 |
5 |
p. 300-
1 p.
|
artikel
|
| 2 |
AO1: IMPACT OF POST-FRACTURE TREATMENT COSTS AND MODEL TIME HORIZON ON COST-EFFECTIVENESS OF OSTEOPOROSIS THERAPIES
|
Grima, DT
|
|
2000
|
3 |
5 |
p. 300-
1 p.
|
artikel
|
| 3 |
AO3: QUALITY OF LIFE AFTER OSTEOPOROTIC FRACTURES IN DUTCH MEN AND WOMEN
|
De Laet, CE
|
|
2000
|
3 |
5 |
p. 300-301
2 p.
|
artikel
|
| 4 |
CH1: COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER
|
Schmitt, C
|
|
2000
|
3 |
5 |
p. 306-
1 p.
|
artikel
|
| 5 |
CH2: RELATING QUALITY ADJUSTED LIFE YEARS TO CONTINGENT VALUATION: ACUTE VERSUS CHRONIC ILLNESSES
|
Franic, DM
|
|
2000
|
3 |
5 |
p. 306-
1 p.
|
artikel
|
| 6 |
CN3: COST-SAVINGS FOR CAPECITABINE DUE TO ORAL ADMINISTRATION IN PREVIOUSLY UNTREATED ADVANCED/ METASTATIC COLORECTAL CANCER
|
Hieke, K
|
|
2000
|
3 |
5 |
p. 306-307
2 p.
|
artikel
|
| 7 |
CV6: A MULTICENTER STUDY OF PHARMACIST DIRECTED INTERVENTIONS IN DYSLIPIDEMIA THERAPY
|
Reeg-Dhingra, MP
|
|
2000
|
3 |
5 |
p. 299-300
2 p.
|
artikel
|
| 8 |
CV5: AN ECONOMIC EVALUATION OF TINZAPARIN COMPARED TO STANDARD HEPARIN IN TREATING PULMONARY EMBOLISM
|
Annemans, L
|
|
2000
|
3 |
5 |
p. 299-
1 p.
|
artikel
|
| 9 |
CV2: EFFECTIVENESS AND COST-EFFECTIVENESS OF EPTIFIBATIDE IN INDIVIDUAL PATIENTS WITH ACUTE CARDIAC ISCHEMIA: THE IMPORTANCE OF RISK STRATIFICATION
|
Kent, DM
|
|
2000
|
3 |
5 |
p. 295-
1 p.
|
artikel
|
| 10 |
CV3: IMPACT OF CARVEDILOL ON INPATIENT RESOURCE USE AND COSTS IN HEART FAILURE
|
Vera-Llonch, M
|
|
2000
|
3 |
5 |
p. 296-
1 p.
|
artikel
|
| 11 |
CV1: IS QUALITY OF LIFE A VALID OUTCOME FOR VARICOSE VEINS SURGERY? RESULTS OF AN INTERNATIONAL EPIDEMIOLOGICAL STUDY
|
Kurz, X
|
|
2000
|
3 |
5 |
p. 295-
1 p.
|
artikel
|
| 12 |
CV4: THE INFLUENCE OF NON-CARDIAC VASCULAR DISEASE ON THE COST-EFFECTIVENESS OF SCREENING FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
|
Davey, PC
|
|
2000
|
3 |
5 |
p. 298-299
2 p.
|
artikel
|
| 13 |
DB2: AGGREGATION OF WILLINGNESS-TO-PAY MEASURED IN DECOMPOSED SCENARIOS
|
Klose, T
|
|
2000
|
3 |
5 |
p. 304-
1 p.
|
artikel
|
| 14 |
DBS: A FIVE YEAR LONGITUDINAL ANALYSIS OF THE HEALTH BENEFITS OF TRANSITIONING TO INSULIN THERAPY SOONER IN THE MANAGEMENT OF NEWLY DIAGNOSED TYPE II DIABETICS
|
Simons, WR
|
|
2000
|
3 |
5 |
p. 304-
1 p.
|
artikel
|
| 15 |
DB1: TWO-PART MODELS FOR DEMAND OF HOSPITAL TREATMENT IN TYPE II DIABETIC PATIENTS
|
Wang, JS
|
|
2000
|
3 |
5 |
p. 303-304
2 p.
|
artikel
|
| 16 |
GS1: AN INVESTIGATION OF FACTORS USED BY PATIENTS FOR DRUG TREATMENT DECISION-MAKING: AN EXAMINATION OF THERAPY OPTIONS FOR ERECTILE DYSFUNCTION
|
Jackson-Kline, SE
|
|
2000
|
3 |
5 |
p. 301-
1 p.
|
artikel
|
| 17 |
GS2: DEVELOPMENT AND VALIDATION OF A TREATMENT SATISFACTION MODULE FOR USE WITH MENOPAUSAL WOMEN
|
McLaughlin-Miley, C
|
|
2000
|
3 |
5 |
p. 301-302
2 p.
|
artikel
|
| 18 |
GS3: THE VALUATION OF DISEASE-SPECIFIC HEALTH STATES TO FACILITATE ECONOMIC EVALUATION OF PHARMACEUTICALS
|
Kok, E
|
|
2000
|
3 |
5 |
p. 302-
1 p.
|
artikel
|
| 19 |
GU3: ERADICATION OF HELICOBACTER PYLORI TO PREVENT PEPTIC ULCERS PRIOR TO NSAID THERAPY-A COST-EFFECTIVENESS ANALYSIS
|
You, JHS
|
|
2000
|
3 |
5 |
p. 305-306
2 p.
|
artikel
|
| 20 |
GU2: HEALTH CARE WORKERS' PERCEPTIONS ON HEALTH STATUS AFTER RENAL TRANSPLANTATION: A COMPARISON WITH TRANSPLANTATION CANDIDATES' EXPECTATIONS
|
Cleemput, I
|
|
2000
|
3 |
5 |
p. 305-
1 p.
|
artikel
|
| 21 |
GU1: THE WILLINGNESS TO PAY FOR REDUCED URGE INCONTINENCE
|
Capri, S
|
|
2000
|
3 |
5 |
p. 304-305
2 p.
|
artikel
|
| 22 |
ID2: COST-EFFECTIVENESS ANALYSIS OF HEXAVALENT MENINGOCOCCAL B OUTER-MEMBRANE-VESICLE VACCINE
|
Bos, JM
|
|
2000
|
3 |
5 |
p. 296-297
2 p.
|
artikel
|
| 23 |
ID1: MODELLING THE COSTS AND EFFECTS OF CMV MANAGEMENT STRATEGIES IN TRANSPLANT RECIPIENTS AS A SUPPORT FOR CURRENT AND FUTURE DECISION-MAKING
|
Annemans, L
|
|
2000
|
3 |
5 |
p. 296-
1 p.
|
artikel
|
| 24 |
ID3: PRELIMINARY EVALUATION OF THE CLINICAL AND ECONOMIC BENEFITS OF UNIVERSAL VARICELLA VACCINATION OF CHILDREN IN GERMANY
|
Banz, K
|
|
2000
|
3 |
5 |
p. 297-
1 p.
|
artikel
|
| 25 |
MD3: A NEW INDEX APPROACH TO MEASURE THE BENEFITS OF DELAYING THE PROGRESSION TO BLINDNESS
|
Althin, R
|
|
2000
|
3 |
5 |
p. 298-
1 p.
|
artikel
|
| 26 |
MD1: AVOIDABLE HOSPITALIZATION: TRENDS AND ETHNIC VARIATIONS IN SINGAPORE, 1991-1998
|
Ng, TP
|
|
2000
|
3 |
5 |
p. 297-298
2 p.
|
artikel
|
| 27 |
MD2: MEASURING REDUCED PRODUCTIVITY DURING PAID LABOR
|
Rothermich, EA
|
|
2000
|
3 |
5 |
p. 298-
1 p.
|
artikel
|
| 28 |
MH1: PATTERNS OF USE OF ANTIDEPRESSANT AND CONCOMITANT PSYCHOTROPICS
|
Fulop, G
|
|
2000
|
3 |
5 |
p. 307-
1 p.
|
artikel
|
| 29 |
MH3: VALIDATION OF A METHODOLOGY FOR ESTIMATING PRODUCTIVITY GAINS FROM IMPROVEMENTS IN HAM-D SCORES
|
Schonfeld, WH
|
|
2000
|
3 |
5 |
p. 308-
1 p.
|
artikel
|
| 30 |
NH2: ATYPICAL ANTIPSYCHOTICS AND THE RISK OF DEVELOPING DIABETES
|
Caro, I
|
|
2000
|
3 |
5 |
p. 307-308
2 p.
|
artikel
|
| 31 |
NR3: ECONOMIC EVALUATION OF TRANSDERMAL FENTANYL IN THE TREATMENT OF CHRONIC NON-CANCER PAIN IN DENMARK
|
Frei, A
|
|
2000
|
3 |
5 |
p. 309-
1 p.
|
artikel
|
| 32 |
NR1: PATIENTS' REPORTED HEALTH STATUS AND UTILITIES FOR AMYOTROPHIC LATERAL SCLEROSIS
|
Green, C
|
|
2000
|
3 |
5 |
p. 308-
1 p.
|
artikel
|
| 33 |
NR2: QUALITY OF LIFE AFTER SUBARACHNOID HEMORRHAGE IN RELATION TO RISK ESTIMATION BEFORE SURGERY
|
Tóth, KJ
|
|
2000
|
3 |
5 |
p. 309-
1 p.
|
artikel
|
| 34 |
PAO2: A COST-COST STUDY COMPARING ETANERCEPT WITH INFLIXIMAB IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS
|
Nuijten, MJC
|
|
2000
|
3 |
5 |
p. 334-
1 p.
|
artikel
|
| 35 |
PAO10: ANNUAL COST OF TREATING CARPAL TUNNEL SYNDROME IN A MANAGED CARE POPULATION
|
Rigoni, G
|
|
2000
|
3 |
5 |
p. 337-
1 p.
|
artikel
|
| 36 |
PAO6: BUDGETARY IMPACT ANALYSIS FOR USE IN REIMBURSEMENT PROCESS OF ETANERCEPT IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS
|
Nuijten, MJC
|
|
2000
|
3 |
5 |
p. 335-336
2 p.
|
artikel
|
| 37 |
PAO1: COST-EFFECTIVENESS ANALYSIS OF NSAIDS VS COX-2 SPECIFIC INHIBITORS AND NSAIDS WITH CO-TREATMENTS TO PREVENT Gl TOXICITY IN THE TREATMENT OF RA
|
Yun, HR
|
|
2000
|
3 |
5 |
p. 333-334
2 p.
|
artikel
|
| 38 |
PAO7: COST-OF-ILLNESS STUDIES IN GERMANY WITH OSTEOPOROSIS AS EXAMPLE
|
Brecht, JG
|
|
2000
|
3 |
5 |
p. 336-
1 p.
|
artikel
|
| 39 |
PAO4: COX-II INHIBITORS AND NSAIDS: FINDINGS OF A NICE SUBMISSION
|
Dickson, AJ
|
|
2000
|
3 |
5 |
p. 335-
1 p.
|
artikel
|
| 40 |
PAO3: DIRECT MEDICAL COST OF CHRONIC POLYARTHRITIS IN GERMANY
|
Berger, K
|
|
2000
|
3 |
5 |
p. 334-335
2 p.
|
artikel
|
| 41 |
PAO8: HOSPITAL COSTS, DAYS, AND POST-ACUTE CARE FOR VERTEBRAL FRACTURES IN WOMEN
|
Burge, RT
|
|
2000
|
3 |
5 |
p. 336-337
2 p.
|
artikel
|
| 42 |
PAO9: IS RESIDRONATE MORE COST-EFFECTIVE THAN ETIDRONATE FOR FRACTURE PREVENTION? A COST-UTILITY ANALYSIS
|
Iglesias, C
|
|
2000
|
3 |
5 |
p. 337-
1 p.
|
artikel
|
| 43 |
PAO5: THE COSTS OF RHEUMATOID ARTHRITIS: IS THERE A NEED FOR STANDARDIZATION OF METHODS?
|
Barbieri, M
|
|
2000
|
3 |
5 |
p. 335-
1 p.
|
artikel
|
| 44 |
PCH1: PAMIDRONATE FOR BREAST CANCER PATIENTS WITH SKELETAL METASTASES: A MARKOV TREE-BASED COST-UTILITY ANALYSIS
|
Liberato, NL
|
|
2000
|
3 |
5 |
p. 350-
1 p.
|
artikel
|
| 45 |
PCH11: PAYER COSTS OF PANCREATIC CANCER IN A NONELDERLY MEDICAID POPULATION
|
Malkin, JD
|
|
2000
|
3 |
5 |
p. 354-
1 p.
|
artikel
|
| 46 |
PCH2: THE LEVEL OF HAEMOGLOBIN (Hb) IN U.K. CANCER PATIENTS CORRELATES POSITIVELY WITH QUALITY OF LIFE (QoL)
|
Lind, M
|
|
2000
|
3 |
5 |
p. 350-351
2 p.
|
artikel
|
| 47 |
PCN15: A METHODOLOGY FOR IMPLEMENTING QUALITY-ADJUSTED DISEASE FREE SURVIVAL (QADFS) WITH MULTIDIMENSIONAL QUALITY OF LIFE (QoL) INSTRUMENTS IN CANCER TRIALS
|
Singh, A
|
|
2000
|
3 |
5 |
p. 355-356
2 p.
|
artikel
|
| 48 |
PCN9: AN APPROACH TO DESIGNING A MULTINATIONAL MODEL FOR THE CURRENT TREATMENT OF BREAST CANCER
|
Noe, LN
|
|
2000
|
3 |
5 |
p. 353-
1 p.
|
artikel
|
| 49 |
PCN12: CHANGES IN OUTPATIENT DRUG COSTS FOR CANCER PATIENTS, 1995 vs 1998
|
Halbert, RJ
|
|
2000
|
3 |
5 |
p. 354-355
2 p.
|
artikel
|
| 50 |
PCN3: COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC PAMIDRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND (COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS)
|
Orlewska, E
|
|
2000
|
3 |
5 |
p. 351-
1 p.
|
artikel
|
| 51 |
PCN8: COST-UTILITY ANALYSIS OF SEVERAL SECOND-LINE CHEMOTHERAPY SCHEMES FOR PATIENTS WITH METASTATIC BREAST CANCER
|
Uyl-de Groot, CA
|
|
2000
|
3 |
5 |
p. 353-
1 p.
|
artikel
|
| 52 |
PCN4: ECONOMIC CONSEQUENCES OF DIFFERENCES IN THE ADVERSE-EVENTS (AE) PROFILE OF CAPECITABINE vs. MAYO CLINIC (M) -REGIMEN IN PREVIOUSLY UNTREATED ADVANCED/ METASTATIC COLORECTAL CANCER.
|
Hieke, K
|
|
2000
|
3 |
5 |
p. 351-352
2 p.
|
artikel
|
| 53 |
PCN5: EVALUATION OF THREE DIFFERENT METHODS OF ASSESSING WILLINGNESS TO PAY FOR A NEW DRUG IN THE GENERAL POPULATION
|
Badia, X
|
|
2000
|
3 |
5 |
p. 352-
1 p.
|
artikel
|
| 54 |
PCN7: FAMILY CAREGIVING COSTS FOR THE ELDERLY WITH CANCER: ESTIMATES FROM A REPRESENTATIVE SAMPLE OF THE UNITED STATES
|
Langa, K
|
|
2000
|
3 |
5 |
p. 352-353
2 p.
|
artikel
|
| 55 |
PCN13: MANAGEMENT OF LUNG CANCER IN FRANCE
|
Schmitt, C
|
|
2000
|
3 |
5 |
p. 355-
1 p.
|
artikel
|
| 56 |
PCN1O: COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC CLODRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND
|
Orlewska, E
|
|
2000
|
3 |
5 |
p. 354-
1 p.
|
artikel
|
| 57 |
PCN6: QUALITY OF LIFE ASSESSMENT OF DOCETAXEL TREATED PATIENTS IN ADVANCED BREAST CANCER
|
Poddubnaya, IV
|
|
2000
|
3 |
5 |
p. 352-
1 p.
|
artikel
|
| 58 |
PCN14: THE USE OF TRANSDERMAL FENTANYL (FEN) VERSUS MORPHINE (MOR) IN CANCER PAIN PATIENTS IN ISRAEL
|
Nuyts, GD
|
|
2000
|
3 |
5 |
p. 355-
1 p.
|
artikel
|
| 59 |
PCU16: ADAPTING A US COST-OFFSET ECONOMIC MODEL FOR OVERACTIVE BLADDER FOR THE EUROPEAN MARKETPLACE
|
Bentkover, JD
|
|
2000
|
3 |
5 |
p. 361-362
2 p.
|
artikel
|
| 60 |
PCV12: A COST COMPARISON STUDY OF AMLODIPINE AND ENALAPRIL IN THE TREATMENT OF HYPERTENSION IN EUROPE
|
Doyle, J
|
|
2000
|
3 |
5 |
p. 314-
1 p.
|
artikel
|
| 61 |
PCV15: ANTI-HYPERTENSIVE AGENTS AND THE RISK OF HIP OR WRIST FRACTURES IN AN OTHERWISE HEALTHY COMMUNITY POPULATION
|
Laer, C
|
|
2000
|
3 |
5 |
p. 315-
1 p.
|
artikel
|
| 62 |
PCV4: COST-EFFECTIVENESS OF DOXAZOSIN IN COMBINATION THERAPY FOR HYPERTENSION TREATMENT IN DIABETIC PATIENTS IN THE UK
|
Casciano, J
|
|
2000
|
3 |
5 |
p. 311-
1 p.
|
artikel
|
| 63 |
PCV22: COST-EFFECTIVENESS OF HMG-CoA REDUCTASE INHIBITORS AND FIBRATES THERAPY IN ELDERLY WOMEN WITH CORONARY ARTERY DISEASE
|
Lazebnik, LB
|
|
2000
|
3 |
5 |
p. 318-
1 p.
|
artikel
|
| 64 |
PCV16: COST-EFFECTIVENESS OF LOW-MOLECULAR WEIGHT HEPARIN VERSUS ORAL ANTICOAGULANTS FOR SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
|
Marchetti, M
|
|
2000
|
3 |
5 |
p. 315-316
2 p.
|
artikel
|
| 65 |
PCV18: COST-EFFECTIVENESS OF PREVENTION OF ATHEROTHROMBOTIC DISEASE WITH ASPIRIN VERSUS CLOPIDOGREL IN GREECE
|
Geitona, M
|
|
2000
|
3 |
5 |
p. 316-
1 p.
|
artikel
|
| 66 |
PCV26: COST OF CARE AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS IN EMILIA ROMAGNA REGION (ITALY): RESULTS FROM THE GREAT STUDY
|
Ambrosioni, E
|
|
2000
|
3 |
5 |
p. 319-
1 p.
|
artikel
|
| 67 |
PCV13: COSTS ASSOCIATED WITH HEALTH SERVICES UTILIZATION IN PATIENTS WITH VARICOSE VEINS
|
Kurz, X
|
|
2000
|
3 |
5 |
p. 314-
1 p.
|
artikel
|
| 68 |
PCV11: DETERMINANTS OF COSTS AND RESOURCE UTILIZATION ASSOCIATED WITH OPEN HEART SURGERY
|
Sokolovic, E
|
|
2000
|
3 |
5 |
p. 313-314
2 p.
|
artikel
|
| 69 |
PCV5: ECONOMIC EVALUATION OF RAMIPRIL IN THE TREATMENT OF PATIENTS AT HIGH RISK OF CARDIOVASCULAR EVENTS
|
Backhouse, ME
|
|
2000
|
3 |
5 |
p. 311-
1 p.
|
artikel
|
| 70 |
PCV6: GENDER DIFFERENCES IN THE QUALITY OF LIFE AND COMPLIANCE WITH ROUTINE TREATMENT OF ESSENTIAL HYPERTENSIVES IN AN ECONOMICALLY DISADVANTAGED COMMUNITY
|
Golubev, SA
|
|
2000
|
3 |
5 |
p. 311-312
2 p.
|
artikel
|
| 71 |
PCV8: HOSPITALIZATION COSTS AFTER FIRST ACUTE CORONARY SYNDROME: A COMBINED MODEL APPROACH
|
Wang, J
|
|
2000
|
3 |
5 |
p. 312-
1 p.
|
artikel
|
| 72 |
PCV7: INCREMENTAL COST-EFFECTIVENESS RATIO IN ESTIMATION SOME HYPOTENSIVE DRUGS
|
Frisman, M
|
|
2000
|
3 |
5 |
p. 312-
1 p.
|
artikel
|
| 73 |
PCV2O: ANNUAL COST OF TREATING HYPERLIPIDEMIA IN A MANAGED CARE POPULATION
|
Shahriar, J
|
|
2000
|
3 |
5 |
p. 317-
1 p.
|
artikel
|
| 74 |
PCV1O: RETROSPECTIVE MEDICAL RECORD REVIEW TO DETERMINE THE “AT GOAL” PATIENTS WITH HYPERTENSION AND/OR DYSLIPIDEMIA
|
Gunnarsson, P
|
|
2000
|
3 |
5 |
p. 313-
1 p.
|
artikel
|
| 75 |
PCV2: POPULATION PROJECTIONS OF CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY ASSOCIATED WITH ROFECOXIB'S EFFECT ON SYSTOLIC BLOOD PRESSURE
|
Russell, MW
|
|
2000
|
3 |
5 |
p. 310-
1 p.
|
artikel
|
| 76 |
PCV9: PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AND FATAL PULMONARY EMBOLISM IN KNEE ARTHROPLASTIES: A COST-EFFECTIVENESS STUDY
|
Nerurkar, J
|
|
2000
|
3 |
5 |
p. 313-
1 p.
|
artikel
|
| 77 |
PCV28: SAVINGS ACHIEVED IN AN HMO SPONSORED PRIMARY CARE BASED DISEASE MANAGEMENT AND CASE MANAGEMENT INITIATIVE
|
Fisher, FJ
|
|
2000
|
3 |
5 |
p. 320-
1 p.
|
artikel
|
| 78 |
PCV29: SUPPORTING IMPLEMENTATION OF PRESCRIPTION GUIDELINES IN MEDICAL WARDS: A RANDOMIZED TRIAL
|
Fontaine, A
|
|
2000
|
3 |
5 |
p. 320-321
2 p.
|
artikel
|
| 79 |
PCV1: THE ATRIAL FIBRILLATION ANTITHROMBOSIS MODEL (AFAM): A GENERAL-PURPOSE TOOL FOR ANALYSIS, POLICY-MAKING, AND EDUCATION
|
Matchar, D
|
|
2000
|
3 |
5 |
p. 309-310
2 p.
|
artikel
|
| 80 |
PCV3: THE COST-EFFECTIVENESS OF TREATING CHLAMYDIA PNEUMONIAE INFECTION FOR THE PREVENTION OF CORONARY HEART DISEASE
|
Sanderson, C
|
|
2000
|
3 |
5 |
p. 310-311
2 p.
|
artikel
|
| 81 |
PCV24: THE COST OF REACHING LDL-C TARGETS IN SPAIN: A COMPARISON AMONG STATINS
|
Smith, D
|
|
2000
|
3 |
5 |
p. 318-319
2 p.
|
artikel
|
| 82 |
PCV25: THE COST OF STROKE IN GREECE IN 1998
|
Kyriopoulos, J
|
|
2000
|
3 |
5 |
p. 319-
1 p.
|
artikel
|
| 83 |
PCV27: TREATMENT OF CHRONIC HEART FAILURE (CHF): IMPROVING SURVIVAL BUT NOT HEALTH-RELATED QUALITY OF LIFE (HRQL)
|
Chassany, O
|
|
2000
|
3 |
5 |
p. 320-
1 p.
|
artikel
|
| 84 |
PCV19: TURKISH PHYSICIAN PRESCRIPTION PATTERNS FOR HYPERTENSION MANAGEMENT
|
Sapci, H
|
|
2000
|
3 |
5 |
p. 317-
1 p.
|
artikel
|
| 85 |
PCV14: USING THE GENERAL PRACTICE RESEARCH DATABASE TO GENERATE AN “AT RISK REGISTER” FOR A PRIMARY CARE STROKE PREVENTION PROGRAM
|
Chapman, SR
|
|
2000
|
3 |
5 |
p. 315-
1 p.
|
artikel
|
| 86 |
PCV17: VARIABILITY IN ABCIXIMAB (REOPRO*) USAGE: EVIDENCE-BASED OR BUDGET-DRIVEN?
|
Zwart-van, Rijkom J
|
|
2000
|
3 |
5 |
p. 316-
1 p.
|
artikel
|
| 87 |
PCV23: VARIATION IN COSTS OF TREATING HYPERCHOLESTEROLEMIC PATIENTS IN FRANCE
|
Smith, D
|
|
2000
|
3 |
5 |
p. 318-
1 p.
|
artikel
|
| 88 |
PCV21: VARIATION IN MEDICAL RESOURCE UTILIZATION IN THE MANAGEMENT OF PULMONARY EMBOLISM
|
Annemans, L
|
|
2000
|
3 |
5 |
p. 317-318
2 p.
|
artikel
|
| 89 |
PDB2: COST-EFFECTIVENESS OF A NEW HUMAN DERMAL REPLACEMENT FOR THE TREATMENT OF DIABETIC FOOT ULCERS: THE CASE OF FRANCE
|
Parée, F
|
|
2000
|
3 |
5 |
p. 338-
1 p.
|
artikel
|
| 90 |
PDB4: EFFECT OF A POLICY CHANGE ON USE OF BLOOD GLUCOSE MONITORS BY DIABETICS WITH MEDICARE COVERAGE
|
Silverman, BG
|
|
2000
|
3 |
5 |
p. 339-
1 p.
|
artikel
|
| 91 |
PDB7: HEALTH RELATED QUALITY OF LIFE IN TYPE 2 DIABETES
|
Holmes, J
|
|
2000
|
3 |
5 |
p. 340-
1 p.
|
artikel
|
| 92 |
PDB5: THE ECONOMIC BURDEN OF TYPE 2 DIABETES ON THE INDIVIDUAL
|
Holmes, J
|
|
2000
|
3 |
5 |
p. 339-
1 p.
|
artikel
|
| 93 |
PDB6: THE FINANCIAL EFFECTS OF INTERFACE AGREEMENTS FOR DIABETES MELLITUS: SOCIOECONOMIC RELEVANCE OF INTENSIVE CONTROLLED INSULIN THERAPY WITH INSULIN LISPRO COMPARED TO REGULAR HUMAN INSULIN
|
Kilburg, A
|
|
2000
|
3 |
5 |
p. 339-340
2 p.
|
artikel
|
| 94 |
PDB3: USE OF BOOTSTRAP IN A COST-OF-ILLNESS STUDY TO DERIVE ACCURACY OF ESTIMATES
|
Wagenpfeil, S
|
|
2000
|
3 |
5 |
p. 338-339
2 p.
|
artikel
|
| 95 |
PDB1: VARIATIONS IN MEDICATION UTILIZATION IN AN OLDER DIABETIC POPULATION
|
Anderson, RT
|
|
2000
|
3 |
5 |
p. 337-338
2 p.
|
artikel
|
| 96 |
PGS1: ALOPECIA, PSYCHOLOGICAL DISTRESS AND QUALITY OF LIFE
|
Taïeb, C
|
|
2000
|
3 |
5 |
p. 340-341
2 p.
|
artikel
|
| 97 |
PGS3: AN ASSESSMENT OF THE RELATION BETWEEN SILDENAFIL USE AND QUALITY OF LIFE DIMENSIONS
|
Gasper, S
|
|
2000
|
3 |
5 |
p. 341-
1 p.
|
artikel
|
| 98 |
PGS5: APPRAISAL OF ERECTILE DYSFUNCTION: WHOSE VALUES SHOULD BE USED?
|
Stolk, E
|
|
2000
|
3 |
5 |
p. 342-
1 p.
|
artikel
|
| 99 |
PGS8: ECONOMIC ASSESSMENT OF THE DIRECT SPECIFIC COST OF BENIGN PROSTATIC HYPERPLASIA IN FRANCE, HEALTH INSURANCE PERSPECTIVE
|
Chopin, D
|
|
2000
|
3 |
5 |
p. 343-
1 p.
|
artikel
|
| 100 |
PGS7: ISSUES IN USING CONJOINT ANALYSIS TO VALUE HEALTH CARE WITHIN CLINICAL STUDIES
|
Girod, I
|
|
2000
|
3 |
5 |
p. 343-
1 p.
|
artikel
|
| 101 |
PGS6: METHODOLOGICAL ISSUES IN EVALUATING CONCEPTUAL EQUIVALENCE: APPLICATION TO THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ)
|
Girod, I
|
|
2000
|
3 |
5 |
p. 342-
1 p.
|
artikel
|
| 102 |
PGS2: PHARMACOECONOMIC MODELING IN ASSISTED REPRODUCTION TECHNOLOGIES: RECOMBINANT FSH VERSUS URINARY FSH
|
Auray, JP
|
|
2000
|
3 |
5 |
p. 341-
1 p.
|
artikel
|
| 103 |
PGS4: PRESENTATION OF THE 23-ITEM WOMEN'S HEALTH QUESTIONNAIRE (WHQ): SCORING AND INTERPRETATION ISSUES
|
Girod, I
|
|
2000
|
3 |
5 |
p. 341-342
2 p.
|
artikel
|
| 104 |
PGU8: ANALYSIS OF THE DIRECT COST GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE
|
Annemans, L
|
|
2000
|
3 |
5 |
p. 359-
1 p.
|
artikel
|
| 105 |
PGU15: COSTS AND RESOURCES ASSOCIATED WITH THE TREATMENT OF OVERACTIVE BLADDER USING RETROSPECTIVE MEDICAL CARE CLAIMS DATA
|
Williamson, T
|
|
2000
|
3 |
5 |
p. 361-
1 p.
|
artikel
|
| 106 |
PGU3: DECISION ANALYSIS OF OMEPRAZOLE VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION FOR TREATING PATIENTS WITH SEVERE GASTROESOPHAGEAL REFLUX DISEASE
|
Cantrell, CR
|
|
2000
|
3 |
5 |
p. 357-
1 p.
|
artikel
|
| 107 |
PGU6: DEVELOPMENT AND INITIAL PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-QUALITY OF LIFE INSTRUMENT (PAGI-QOL) IN Gl PATIENTS
|
de la Loge, C
|
|
2000
|
3 |
5 |
p. 358-
1 p.
|
artikel
|
| 108 |
PGU11: DEVELOPMENT AND PRELIMINARY PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-SYMPTOM SEVERITY INDEX (PAGI-SYM) IN GASTROPARESIS
|
Schmier, J
|
|
2000
|
3 |
5 |
p. 360-
1 p.
|
artikel
|
| 109 |
PGU2: DEVELOPMENT AND PRELIMINARY PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-SYMPTOM SEVERITY INDEX (PAGI-SYM) IN Gl PATIENTS
|
Rentz, A
|
|
2000
|
3 |
5 |
p. 356-357
2 p.
|
artikel
|
| 110 |
PGU13: ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH OMEPRAZOLE FOR THE ACUTE TREATMENT OF PATIENTS WITH NON-ENDOSCOPED GORD IN THE UK
|
Wahlqvist, P
|
|
2000
|
3 |
5 |
p. 360-361
2 p.
|
artikel
|
| 111 |
PGU9: EVALUATION OF THE DIRECT COST OF CARE FOR PATIENTS SUFFERING FROM HEMORRHOIDS
|
Taïeb, C
|
|
2000
|
3 |
5 |
p. 359-
1 p.
|
artikel
|
| 112 |
PGU17: FACTORS ASSOCIATED WITH SELECTING MEDICATION TO TREAT PATIENTS NEWLY DIAGNOSED WITH OVERACTIVE BLADDER
|
Lenderking, WR
|
|
2000
|
3 |
5 |
p. 362-
1 p.
|
artikel
|
| 113 |
PGU7: IN FINLAND, SWEDEN AND THE UK, ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH OMEPRAZOLE FOR THE ACUTE TREATMENT OF PATIENTS WITH REFLUX OESOPHAGITIS
|
Wahlqvist, P
|
|
2000
|
3 |
5 |
p. 358-
1 p.
|
artikel
|
| 114 |
PGU12: IN FINLAND, SWEDEN AND THE UK, ON DEMAND TREATMENT WITH ESOMEPRAZOLE IS COST-EFFECTIVE IN PATIENTS WITH GORD WITHOUT OESOPHAGITIS
|
Wahlqvist, P
|
|
2000
|
3 |
5 |
p. 360-
1 p.
|
artikel
|
| 115 |
PGU1: IS HEALTH-RELATED QUALITY OF LIFE (HRQL) IMPROVED BY GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) DRUGS?
|
Chassany, O
|
|
2000
|
3 |
5 |
p. 356-
1 p.
|
artikel
|
| 116 |
PGU14: MODELLING OF AN ANTIOBESITY TREATMENT: COST-EFFECTIVENESS MODEL IN THE UK
|
Knight, C
|
|
2000
|
3 |
5 |
p. 361-
1 p.
|
artikel
|
| 117 |
PGU1O: IRRITABLE BOWEL SYNDROME (IBS) IN GERMANY: A COST OF ILLNESS STUDY
|
Pirk, O
|
|
2000
|
3 |
5 |
p. 359-360
2 p.
|
artikel
|
| 118 |
PGU18: PREVALENCE OF BLADDER CONTROL PROBLEMS IN A LARGE GERMAN POPULATION SAMPLE
|
Goepel, M
|
|
2000
|
3 |
5 |
p. 362-
1 p.
|
artikel
|
| 119 |
PGU5: THE BURDEN OF ILLNESS OF IRRITABLE BOWEL SYNDROME (IBS) USING THE ROME II CRITERIA
|
Badia, X
|
|
2000
|
3 |
5 |
p. 357-358
2 p.
|
artikel
|
| 120 |
PGU4: UTILIZATION AND COSTS OF GASTROINTESTINAL DRUGS IN RELATION TO HELICOBACTER-PYLORI ERADICATION; PHARMACOECONOMIC ANALYSIS FOR THE NETHERLANDS
|
Postma, MJ
|
|
2000
|
3 |
5 |
p. 357-
1 p.
|
artikel
|
| 121 |
PHDE4: PHARMACOECONOMIC EVALUATION OF CALCIPOTRIOL AND UVB IN THE TREATMENT OF PSORIASIS IN THE NETHERLANDS
|
de Rie, MA
|
|
2000
|
3 |
5 |
p. 376-
1 p.
|
artikel
|
| 122 |
PHDH7: INTERNATIONAL COMPARISON OF PHARMACOECONOMIC GUIDELINES: CONSENSUS, DIVERGENCE AND PRACTICAL IMPLICATIONS
|
Baron, F
|
|
2000
|
3 |
5 |
p. 370-
1 p.
|
artikel
|
| 123 |
PHH7: TREATMENT PATTERNS OF PATIENTS WITH SCHIZOPHRENIA AND SCHIZO-AFFECTIVE DISORDER ACROSS 15 COUNTRIES
|
Patel, A
|
|
2000
|
3 |
5 |
p. 346-
1 p.
|
artikel
|
| 124 |
PID1: ASSOCIATED OUTCOMES OF INFLUENZA-LIKE-ILLNESS AND CLINICAL INFLUENZA IN ITALY
|
Costa, B
|
|
2000
|
3 |
5 |
p. 321-
1 p.
|
artikel
|
| 125 |
PID6: CANADIAN COST-EFFECTIVENESS OF COMBINATION RIBAVIRIN/INTERFERON ALPHA-2B THERAPY FOR TREATMENT-NAIVE VIRAL HEPATITIS C
|
Marotta, PJ
|
|
2000
|
3 |
5 |
p. 323-
1 p.
|
artikel
|
| 126 |
PID10: COST-EFFECTIVENESS ANALYSIS OF ANTIBIOTIC PROPHYLAXIS IN INTRA-ABDOMINAL SURGERY
|
Rozenson, O
|
|
2000
|
3 |
5 |
p. 324-325
2 p.
|
artikel
|
| 127 |
PID8: COST-EFFECTIVENESS OF CIPROFLOXACIN + HYDROCORTISON VERSUS NEOMYCIN + POLYMIXIN + HYDROCORTISON IN THE TREATMENT OF ACUTE OTITIS EXTERNA
|
Lafuma, A
|
|
2000
|
3 |
5 |
p. 324-
1 p.
|
artikel
|
| 128 |
PID13: COST-EFFECTIVENESS OF GANCICLOVIR IN PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER LIVER TRANSPLANTATION: A BAYESIAN APPROACH
|
Vanness, DJ
|
|
2000
|
3 |
5 |
p. 326-
1 p.
|
artikel
|
| 129 |
PID3: COST-EFFECTIVENESS OF HEPATITIS B VACCINATION IN THE NETHERLANDS
|
De WitG, A
|
|
2000
|
3 |
5 |
p. 321-322
2 p.
|
artikel
|
| 130 |
PID4: HOSPITAL ANTIBIOTICS UTILIZATION EVALUATION
|
Caicoya, M
|
|
2000
|
3 |
5 |
p. 322-
1 p.
|
artikel
|
| 131 |
PID5: MEDICO-ECONOMIC MODELLING OF INFLUENZA MANAGEMENT IN EUROPE: METHODOLOGY USED IN FRANCE AND GERMANY
|
Megas, F
|
|
2000
|
3 |
5 |
p. 322-323
2 p.
|
artikel
|
| 132 |
PID14: MODELING PHYSICIAN PREFERENCES IN ANTIBIOTIC CHOICE
|
Morris, MS
|
|
2000
|
3 |
5 |
p. 326-
1 p.
|
artikel
|
| 133 |
PID7: MULTITHERAPIES: TOWARDS COST-SAVING STRATEGIES IN REAL LIFE?
|
Le Pen, C
|
|
2000
|
3 |
5 |
p. 323-324
2 p.
|
artikel
|
| 134 |
PID9: PATIENTS' COMPLIANCE AND COST-EFFECTIVENESS OF SELECTED ORAL ANTIBACTERIALS IN INPATIENT TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS
|
Schadlich, PK
|
|
2000
|
3 |
5 |
p. 324-
1 p.
|
artikel
|
| 135 |
PID2: PHARMACOECONOMIC EVALUATION OF IMMUNOPROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK INFANTS
|
Doshi, J
|
|
2000
|
3 |
5 |
p. 321-
1 p.
|
artikel
|
| 136 |
PID12: THE IMPACT OF PRICE ELASTICITY OF DEMAND ON CONSUMPTION-AMPICILLIN/ AMOXICILLIN MARKET SURVEY IN BULGARIA, 1995 AND 1999
|
Borissov, B
|
|
2000
|
3 |
5 |
p. 325-326
2 p.
|
artikel
|
| 137 |
PID11: THE PEACE PROJECT (PRESCRIPTION AND EFFECTIVENESS OF ANTIBIOTIC IN CLINICAL EXPERIENCE): RESULTS OF THE FEASIBILITY STUDY
|
Degli Esposti, L
|
|
2000
|
3 |
5 |
p. 325-
1 p.
|
artikel
|
| 138 |
PMDE3: COST-EFFECTIVENESS ANALYSIS OF CONTINOUS TERBINAFINE VS INTERMITTENT ITRACONAZOLE IN THE TREATMENT OF TOENAIL ONYCHOMYCOSIS IN POLAND
|
Orlewska, E
|
|
2000
|
3 |
5 |
p. 375-376
2 p.
|
artikel
|
| 139 |
PMDE5: COST-EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA
|
Gouveia Pinto, C
|
|
2000
|
3 |
5 |
p. 376-
1 p.
|
artikel
|
| 140 |
PMDE6: EVALUATION OF THE VALIDITY OF RETROSPECTIVE QOL OUTCOMES
|
Krabbe, PFM
|
|
2000
|
3 |
5 |
p. 377-
1 p.
|
artikel
|
| 141 |
PMDE1: SOCIETAL IMPACT OF LOST EARNINGS ASSOCIATED WITH AGE-RELATED MACULOPATHY
|
Hua, K
|
|
2000
|
3 |
5 |
p. 374-375
2 p.
|
artikel
|
| 142 |
PMDE2: THE COST OF GLAUCOMA TREATMENT IN POLAND-RESULTS FROM OBSERVATIONAL STUDY
|
Orlewska, E
|
|
2000
|
3 |
5 |
p. 375-
1 p.
|
artikel
|
| 143 |
PMDH6: AN ECONOMIC EVALUATION OF PHARMACEUTICAL COST CONTAINMENT POLICIES IN ALBERTA, CANADA
|
Fassbender, K
|
|
2000
|
3 |
5 |
p. 370-
1 p.
|
artikel
|
| 144 |
PMDH9: ATLAS OF AVOIDABLE DEATHS IN ITALY
|
Bamfi, F
|
|
2000
|
3 |
5 |
p. 371-
1 p.
|
artikel
|
| 145 |
PMDH4: DIFFERING LEVELS OF PATIENT SATISFACTION WITH PHARMACY SERVICES IN A MANAGED CARE ORGANIZATION
|
Fincham, JE
|
|
2000
|
3 |
5 |
p. 369-
1 p.
|
artikel
|
| 146 |
PMDH8: DO DECISION-MAKERS FIND ECONOMIC EVALUATIONS USEFUL? RESULTS OF FOCUS GROUP RESEARCH IN THE UK
|
Drummond, MF
|
|
2000
|
3 |
5 |
p. 370-371
2 p.
|
artikel
|
| 147 |
PMDH1: NICE REQUIREMENTS FOR COST-EFFECTIVENESS EVIDENCE: POTENTIAL SAMPLE SIZE IMPLICATIONS OF GENERATING TRIAL-BASED EVIDENCE
|
Backhouse, ME
|
|
2000
|
3 |
5 |
p. 368-
1 p.
|
artikel
|
| 148 |
PMDH1O: REIMBURSED DRUG REGULATION: COMPARING TWO MODELS FOR CONTROL DRUGS CONSUMPTION IN ISRAEL USING PERMEATION COEFFICIENT PARAMETER.
|
Klang, S
|
|
2000
|
3 |
5 |
p. 371-372
2 p.
|
artikel
|
| 149 |
PMDH5: TEMPORAL TRENDS AND ETHNIC VARIATIONS IN AMENABLE MORTALITY IN SINGAPORE FROM 1965 TO 1994: THE IMPACT OF HEALTH CARE IN TRANSITION
|
Niti, M
|
|
2000
|
3 |
5 |
p. 369-370
2 p.
|
artikel
|
| 150 |
PMDH3: THE USE OF SURROGATE ENDPOINT DATA IN EVALUATING TREATMENT EFFICACY: IMPACT ON DECISION-MAKING AND EXPENDITURE WITHIN THE AUSTRALIAN PHARMACEUTICAL BENEFITS SCHEME
|
Lopert, R
|
|
2000
|
3 |
5 |
p. 368-369
2 p.
|
artikel
|
| 151 |
PMDM2: GUIDING PRINCIPLES TO COMPARE THE EFFICACY OF NOVEL DRUGS USING RCT MATCHED ARM COMPARISONS
|
Laer, C
|
|
2000
|
3 |
5 |
p. 373-374
2 p.
|
artikel
|
| 152 |
PMDM4: MEASUREMENTS OF HEALTH STATUS IN DENMARK
|
Wittrup-Jensen, KU
|
|
2000
|
3 |
5 |
p. 374-
1 p.
|
artikel
|
| 153 |
PMDM1: POWER AND SAMPLE SIZE CALCULATIONS FOR A CLINICAL TRIAL CONSIDERING COST-EFFECTIVENESS AND STATISTICAL ERRORS
|
Kamae, I
|
|
2000
|
3 |
5 |
p. 373-
1 p.
|
artikel
|
| 154 |
PMDM3: PROJECTING ECONOMIC RESULTS OF A EUROPEAN TRIAL TO THE UNITED STATES: ISSUES AND METHODS
|
Sorensen, S
|
|
2000
|
3 |
5 |
p. 374-
1 p.
|
artikel
|
| 155 |
PMDP2: CONSUMER USE OF THE INTERNET FOR HEALTHCARE INFORMATION
|
Donohue, JA
|
|
2000
|
3 |
5 |
p. 372-
1 p.
|
artikel
|
| 156 |
PMDP3: THE FRENCH HEALTH UTILITIES INDEX MARK 3
|
Le Gales, C
|
|
2000
|
3 |
5 |
p. 372-373
2 p.
|
artikel
|
| 157 |
PMDP4: THE INFLUENCE OF NON-COMPLIANCE ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DRUG THERAPIES
|
Hughes, D
|
|
2000
|
3 |
5 |
p. 373-
1 p.
|
artikel
|
| 158 |
PMDP1: WILLINGNESS TO PAY FOR AVOIDING ADVERSE EFFECTS OF DRUGS
|
Rodriguez, R
|
|
2000
|
3 |
5 |
p. 372-
1 p.
|
artikel
|
| 159 |
PMDQ2: CHANGE AND STATUS IN QUALITY OF LIFE (CASINQOL) IN NORTHERN SWEDEN IN 1997/98: BY DECLARED REGULARITY OF PHARMACEUTICAL DRUG INTAKE
|
Kempe, A
|
|
2000
|
3 |
5 |
p. 366-
1 p.
|
artikel
|
| 160 |
PMDQ4: CHANGE AND STATUS IN QUALITY OF LIFE (CASINQOL) IN NORTHERN SWEDEN IN 1997/98: PSYCHOMETRICS OF THE MINI QLCS ASSESSMENT BATTERY APPLIED
|
Hörnquist, JO
|
|
2000
|
3 |
5 |
p. 367-
1 p.
|
artikel
|
| 161 |
PMDQ1: GENERAL POPULATION-BASED QUALITY OF LIFE MEASUREMENTS USING THE EQ-5D QUESTIONNAIRE
|
Szende, A
|
|
2000
|
3 |
5 |
p. 366-
1 p.
|
artikel
|
| 162 |
PMDQ3: HEALTH-RELATED QUALITY OF LIFE AMONG FRENCH PATIENTS HOSPITALIZED IN INTERNAL MEDICINE
|
Chassany, O
|
|
2000
|
3 |
5 |
p. 366-367
2 p.
|
artikel
|
| 163 |
PMDQ5: MONETARY VALUE OF QUALITY OF LIFE IMPROVEMENTS
|
Lachaine, J
|
|
2000
|
3 |
5 |
p. 367-
1 p.
|
artikel
|
| 164 |
PMH4: CLINICAL, HUMANISTIC, AND ECONOMIC OUTCOMES ASSOCIATED WITH LONG-TERM TREATMENT OF MANIA WITH OLANZAPINE
|
Namjoshi, M
|
|
2000
|
3 |
5 |
p. 345-
1 p.
|
artikel
|
| 165 |
PMH14: COST OF CARE IN SCHIZOPHRENIA PATIENTS—RESULTS FROM THE NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA
|
Atkinson, MA
|
|
2000
|
3 |
5 |
p. 348-349
2 p.
|
artikel
|
| 166 |
PMH17: COST OF TREATING SIDE EFFECTS OF SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs) IN A HEALTH MAINTENANCE ORGANIZATION (HMO)
|
Rascati, K.L
|
|
2000
|
3 |
5 |
p. 349-350
2 p.
|
artikel
|
| 167 |
PMH12: DATA TRIANGULATION IN THE ASSESSMENT OF SUBSTANCE ABUSE TREATMENT OUTCOMES IN ADOLESCENT POPULATIONS
|
Ciesla, J
|
|
2000
|
3 |
5 |
p. 347-348
2 p.
|
artikel
|
| 168 |
PMH11: DEINSTITUTIONALIZATION MODEL IN SCHIZOPHRENIA: COST-CONSEQUENCES OF INTENSIVE CASE MANAGEMENT VERSUS STANDARD CASE MANAGEMENT
|
Llorca, PM
|
|
2000
|
3 |
5 |
p. 347-
1 p.
|
artikel
|
| 169 |
PMH15: ECONOMIC EVALUATION OF REBOXETINE FOR TREATING MAJOR DEPRESSION
|
Sheriff, SK
|
|
2000
|
3 |
5 |
p. 349-
1 p.
|
artikel
|
| 170 |
PMH3: GLOBAL INDEX OF SAFETY (GIS): A NEW INSTRUMENT TO ASSESS DRUG SAFETY: APPLICATION TO A PROSPECTIVE PHARMACOEPIDEMIOLOGICAL STUDY (EFESO)
|
Sacristan, JA
|
|
2000
|
3 |
5 |
p. 344-
1 p.
|
artikel
|
| 171 |
PMH5: IMPACT OF AMISULPRIDE ON HEALTH CARE RESOURCES IN SCHIZOPHRENIA: PRELIMINARY RESULTS OF A FRENCH STUDY
|
Levy, E
|
|
2000
|
3 |
5 |
p. 345-
1 p.
|
artikel
|
| 172 |
PMH8: PHARMACOECONOMIC MODELLING IN DEPRESSION: AID OR TRAP
|
Toumi, M
|
|
2000
|
3 |
5 |
p. 346-
1 p.
|
artikel
|
| 173 |
PMH16: RELAPSE IN SCHIZOPHRENIA: COSTS AND QUALITY OF LIFE
|
Brugha, T
|
|
2000
|
3 |
5 |
p. 349-
1 p.
|
artikel
|
| 174 |
PMH10: SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC TREATMENT AND COMPLIANCE IN SCHIZOPHRENIA
|
Garcia-Cabeza, I
|
|
2000
|
3 |
5 |
p. 346-347
2 p.
|
artikel
|
| 175 |
PMH1: THE IMPACT OF DEMENTIA ON THE QUALITY OF LIFE OF CAREGIVERS OF ELDERLY PEOPLE
|
Scuvee-Moreau, J
|
|
2000
|
3 |
5 |
p. 343-344
2 p.
|
artikel
|
| 176 |
PMH13: THE MEDICAL COSTS OF DEMENTIA IN BELGIUM: RESULTS OF THE NADES STUDY
|
Scuvee-Moreau, J
|
|
2000
|
3 |
5 |
p. 348-
1 p.
|
artikel
|
| 177 |
PNH6: ANTIPSYCHOTIC TREATMENT, ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE
|
Badia, X
|
|
2000
|
3 |
5 |
p. 345-346
2 p.
|
artikel
|
| 178 |
PNH2: EVALUATION OF THE CES-D IN SIX COUNTRIES USING RASCH ITEM RESPONSE THEORY (IRT) ANALYSIS
|
Bushnell, DM
|
|
2000
|
3 |
5 |
p. 344-
1 p.
|
artikel
|
| 179 |
PNR8: A CANADIAN ADAPTATION OF A DECISION ANALYTIC MODEL FOR THE ECONOMIC EVALUATION OF OPIOIDS FOR CHRONIC PAIN
|
Neighbors, DM
|
|
2000
|
3 |
5 |
p. 365-
1 p.
|
artikel
|
| 180 |
PNR3: A COST MINIMIZATION MODEL FOR 2:1 THERAPEUTIC INTERCHANGE PROTOCOLS OF MEDICATIONS WITH HIGHLY VARIABLE DOSING REGIMENS
|
Gordon, M
|
|
2000
|
3 |
5 |
p. 363-364
2 p.
|
artikel
|
| 181 |
PNR4: A STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE ACUTE TREATMENT STRATEGIES FOR MIGRAINE: THE DISABILITY IN STRATEGIES FOR CARE (DISC) STUDY
|
Sculpher, MI
|
|
2000
|
3 |
5 |
p. 364-
1 p.
|
artikel
|
| 182 |
PNR7: COST-EFFECTIVENESS ANALYSIS OF ENTACAPONE IN ADVANCED PARKINSON'S DISEASE A MARKOV PROCESS ANALYSIS
|
Nuijten, MJC
|
|
2000
|
3 |
5 |
p. 365-
1 p.
|
artikel
|
| 183 |
PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)
|
Orlewska, E
|
|
2000
|
3 |
5 |
p. 362-363
2 p.
|
artikel
|
| 184 |
PNR6: SUBJECTIVE AND OBJECTIVE QUALITY OF LIFE CHANGE SCORES IN A SHORT-TERM EPILEPSY STUDY
|
Abetz, LN
|
|
2000
|
3 |
5 |
p. 364-365
2 p.
|
artikel
|
| 185 |
PNR5: THE LONG-TERM ECONOMIC IMPACT OF TREATING ALZHEIMER'S PATIENTS IN SWEDEN WITH GALANTAMINE
|
Garfield, FB
|
|
2000
|
3 |
5 |
p. 364-
1 p.
|
artikel
|
| 186 |
PNR2: THE ROLE OF COGNITIVE METHODS IN THE DESIGN OF CONJOINT ANALYSIS TO EVALUATE EPILEPSY TREATMENTS
|
Mansfield, C
|
|
2000
|
3 |
5 |
p. 363-
1 p.
|
artikel
|
| 187 |
PRS4: A HEALTH ECONOMIC MODEL TO DESCRIBE THE CURRENT AND EXPECTED BURDEN OF COPD
|
Annemans, L
|
|
2000
|
3 |
5 |
p. 328-
1 p.
|
artikel
|
| 188 |
PRS7: AN ECONOMIC IMPACT OF A DUR INTERVENTION ON THE PHARMACOLOGICAL MANAGEMENT OF ASTHMA IN CHILDREN
|
Raut, MK
|
|
2000
|
3 |
5 |
p. 329-
1 p.
|
artikel
|
| 189 |
PRS13: ANNUAL COST OF TREATING RHINITIS IN A MANAGED CARE POPULATION
|
Bataoel, J
|
|
2000
|
3 |
5 |
p. 331-
1 p.
|
artikel
|
| 190 |
PRS14: ASTHMA AND ANTI-ASTHMA DRUG USE IN HUNGARY
|
Meszaros, A
|
|
2000
|
3 |
5 |
p. 331-332
2 p.
|
artikel
|
| 191 |
PRS2: COST-EFFECTIVENESS ANALYSIS OF BASIC AND IMMUNOTROPIC THERAPY IN CHILDREN WITH BRONCHIAL ASTHMA
|
Prosekova, E
|
|
2000
|
3 |
5 |
p. 327-
1 p.
|
artikel
|
| 192 |
PRS5: COST-EFFECTIVENESS OF EMEDASTINE VERSUS LEVOCABASTINE IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS
|
Gouveia Pinto, C
|
|
2000
|
3 |
5 |
p. 328-
1 p.
|
artikel
|
| 193 |
PRS12: COST OF ILLNESS ON PATIENTS IN A PUBLIC HOSPITAL WITH SEVERE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAY DISEASE
|
Lee, KKC
|
|
2000
|
3 |
5 |
p. 331-
1 p.
|
artikel
|
| 194 |
PRS16: ECONOMIC IMPACT OF THE RESPIRATORY SYNCYTIAL VIRUS DISEASE, FRENCH SOCIETAL PERSPECTIVE
|
Levy, E
|
|
2000
|
3 |
5 |
p. 332-333
2 p.
|
artikel
|
| 195 |
PRS17: EPIDEMIOLOGY AND COSTS OF BRONCHIAL ASTHMA AND CHRONIC BRONCHITIS IN GERMANY
|
Weissflog, D
|
|
2000
|
3 |
5 |
p. 333-
1 p.
|
artikel
|
| 196 |
PRS3: EUROQOL EQ-5D: DISCRIMINANT VALIDITY IN RESPIRATORY DISEASE
|
Laybourn, M
|
|
2000
|
3 |
5 |
p. 327-328
2 p.
|
artikel
|
| 197 |
PRS11: IMPACT OF BRONCHIAL ASTHMA ON CHILD'S QUALITY OF LIFE
|
Prosekova, E
|
|
2000
|
3 |
5 |
p. 330-331
2 p.
|
artikel
|
| 198 |
PRS1O: AGE AND GENDER DIFFERENCES IN UTILIZATION OF ASTHMA MEDICATION IN CHILDREN AND YOUNG ADULTS IN TAYSIDE, SCOTLAND
|
McNaughton, DM
|
|
2000
|
3 |
5 |
p. 330-
1 p.
|
artikel
|
| 199 |
PRS15: OUTCOMES RESEARCH STUDY ASSESSING RESOURCE UTILIZATION FOR THE TREATMENT OF ASTHMA EXACERBATION IN PRIMARY CARE IN SPAIN
|
Kielhorn, A
|
|
2000
|
3 |
5 |
p. 332-
1 p.
|
artikel
|
| 200 |
PRS9: PROBLEMATIC ISSUES OF THE QUALITY OF ASTHMA MANAGEMENT IN RURAL AREAS IN GREECE
|
Karokis, A
|
|
2000
|
3 |
5 |
p. 330-
1 p.
|
artikel
|
| 201 |
PRS6: QUALITY OF LIFE AND TREATMENT SATISFACTION MEASUREMENT WITH ASTHMA PATIENTS: RESULTS FROM A COMPREHENSIVE LITERATURE REVIEW
|
Abetz, LN
|
|
2000
|
3 |
5 |
p. 328-329
2 p.
|
artikel
|
| 202 |
PRS1: TO COMPARE AND CONTRAST THE QUALITY OF LIFE (QOL) OF INDIVIDUALS WITH CHRONIC BRONCHITIS, DURING THE STABLE PHASE AND ACUTE EXACERBATIONS
|
Wild, D
|
|
2000
|
3 |
5 |
p. 326-327
2 p.
|
artikel
|
| 203 |
PRS8: TREATMENT AND ASSOCIATED COSTS OF NEWLY DIAGNOSED COPD PATIENTS IN A MANAGED CARE POPULATION
|
Cox, F
|
|
2000
|
3 |
5 |
p. 329-330
2 p.
|
artikel
|
| 204 |
PRS18: USE OF PHARMACOTHERAPY AS AN ASTHMA SEVERITY MEASURE IN A RETROSPECTIVE ANALYSIS
|
Bataoel, J
|
|
2000
|
3 |
5 |
p. 333-
1 p.
|
artikel
|
| 205 |
RS1: COMPARISON OF IMPUTATION METHODS FOR MISSING ASTHMA QUALITY OF LIFE DATA
|
Runken, MC
|
|
2000
|
3 |
5 |
p. 302-
1 p.
|
artikel
|
| 206 |
RS3: QUALITY OF LIFE OF ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE
|
Svensson, K
|
|
2000
|
3 |
5 |
p. 303-
1 p.
|
artikel
|
| 207 |
RS2: SYMPTOM-BASED OUTCOME MEASURES FOR ASTHMA
|
McKenzie, L
|
|
2000
|
3 |
5 |
p. 303-
1 p.
|
artikel
|
Tijdschrift beschrijving